Co-stimulation of LPAR1 and S1PR1/3 increases the transplantation efficacy of human mesenchymal stem cells in drug-induced and alcoholic liver diseases

Table 1 Tumour incidence rate after human mesenchymal stem cell (MSCs) transplantation in healthy, acute liver failure (ALF), and alcoholic liver disease (ALD) non-obese diabetic severe combined immune-deficient (NOD/SCID) mice

Model	Test item	Injected cell number	No. of tumour-bearing mice^a	Tumour incidence rate (%)
Healthy mice	MRC-5^b	1 × 10⁷	0/12	0
	hADMSCs	1 × 10⁷	0/12	0
	hADMSCs with LPA/S1P^c	1 × 10⁷	0/12	0
	ES-D3^d	1 × 10⁷	10/10	100
ALF model	MRC-5	1 × 10⁷	0/9	0
	hADMSCs	1 × 10⁷	0/12	0
	hADMSCs with LPA/S1P	1 × 10⁷	0/15	0
	ES-D3	1 × 10⁷	9/9	100
ALD model	MRC-5	1 × 10⁷	0/12	0
	hADMSCs	1 × 10⁷	0/12	0
	hADMSCs with LPA/S1P	1 × 10⁷	0/12	0
	ES-D3	1 × 10⁷	11/11	100

hADMSC, human adipose-derived mesenchymal stem cell; LPA, lysophosphatidic acid; S1P, sphingosine-1-phosphate
^aDead mice during experiments were not calculated
^bNegative control group
^cPre-treated with 5 μM LPA and 0.25 μM S1P for 2 h before stem cell transplantation
^dPositive control group

ISSN: 1757-6512